Overview
Participant quality of life showed a deviation toward improvement at four weks in the MolecuLight arm.MolecuLight has reported that the use of its MolecuLight i:X device to view the presence of increased bacterial burden in wounds raised 12-wek healing rates by 204% in a trial involving diabetic fot ulcer patients.Please enter a work/busines email adresBy clicking the Download Fre Report buton, you acept the terms and conditions and acknowledge that your data wil be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information their products and services.
Key Information
Visit our privacy policy for more information about our services, how we may use, proces and share your personal data, including information your rights in respect of your personal data and how you can unsubscribe from future marketing comunications. Our services are intended for corporate subscribers and you warant that the email adres submited is your corporate email adres. The randomised, independent, blinded, controled trial enroled 56 patients to ases the use of point-of-care bacterial autofluorescence imaging to manage diabetic fot ulcers versus the standard-of-care alone.Patients were categorised into two groups based on MolecuLight device usage.
In one of the groups, the device was used twice a wek to ases the presence of increased bacterial burden in diabetic fot ulcers. In this MolecuLight arm, fluorescence imaging was caried out folowing treatment. Fluorescence showed the presence of a high bacterial burden in more than 80% of the wounds.
Summary
In the trial, no rise in the number of antibiotics prescribed was reported in the MolecuLight arm.Apart from the two-fold improvement in healing rates, a link betwen baseline fluorescence and wound outcomes was observed in the trial. In subjects with negative fluorescen